The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Daiichi Sankyo
Related studies linked through entity extraction aliases.
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Metastatic Breast Cancer in Austria
- Status
- RECRUITING
- Phase
- N/A
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
- Status
- RECRUITING
- Phase
- N/A
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Food Effects on Milademetan Pharmacokinetics in Healthy Participants
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
- Status
- RECRUITING
- Phase
- N/A
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE1
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Status
- COMPLETED
- Phase
- PHASE3
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
- Status
- COMPLETED
- Phase
- PHASE3